This clinical trial is focused on studying the immune response and safety of a new vaccine for preventing infections caused by the measles, mumps, rubella, and varicella (chickenpox) viruses. The study involves healthy children aged 4 to 6 years. The new vaccine is being compared to an existing vaccine called ProQuad, which is already available on the market. The new vaccine contains live, weakened strains of the viruses that cause these diseases, similar to the ProQuad vaccine.
The purpose of the study is to evaluate how well the new vaccine works in generating an immune response, which is the body’s way of defending against infections. The study will also assess the safety of the vaccine by monitoring any side effects that may occur. Children participating in the study will receive either the new vaccine or the ProQuad vaccine. The vaccines are given as a single injection under the skin, and the study will follow the children for several months to observe their immune response and any side effects.
Throughout the study, researchers will measure the levels of antibodies, which are proteins made by the immune system to fight infections, in the children’s blood. These measurements will help determine how effectively the vaccines protect against the viruses. The study will also track any common side effects, such as fever or rash, and any serious adverse events that might occur. The goal is to ensure that the new vaccine is both effective and safe for use in children.



Latvia
Spain